Improda Nicola, Chioma Laura, Capalbo Donatella, Bizzarri Carla, Salerno Mariacarolina
Neuro-Endocrine Diseases and Obesity Unit, Department of Neurosciences, Santobono- Pausilipon Children's Hospital, Napoli, Italy.
Endocrinology Unit, University Hospital Pediatric Department, Bambino Gesù Children's Hospital, Rome, Italy.
J Endocrinol Invest. 2025 Jan;48(1):37-52. doi: 10.1007/s40618-024-02461-9. Epub 2024 Oct 1.
Glucocorticoids (GCs) are commonly used for several acute and chronic pediatric diseases. However, chronic treatment may result in hypothalamic-pituitary-adrenal axis (HPA) dysfunction. Glucocorticoid-induced adrenal insufficiency (GI-AI) is indeed the most frequent cause of adrenal insufficiency (AI) in children, possibly resulting in a life-threatening event such as adrenal crisis (AC). It is generally underestimated, especially when using non-systemic glucocorticoid formulations. This review aims at summarizing current evidence on the effects of long-term GC treatment on the HPA axis, management of GC tapering and assessment of the HPA recovery.
We conducted a narrative review of the relevant literature focusing on pathogenic mechanisms, predictive factors, diagnosis and treatment of GI-AI.
All types of GCs, whatever the route of administration, may have suppressive effects on the HPA axis, especially when compounds with higher potency and long half-life are used. Moreover, chronic GC administration is the most common cause of Cushing syndrome in children. In order to overcome the risk of GI-AI, slow withdrawal of GCs is necessary. When approaching the replacement dose, it is recommended to switch to shorter half-life formulations such as hydrocortisone. Assessment of HPA axis recovery with basal and stimulated cortisol levels may help detecting children at risk of AC that may require hydrocortisone supplementation.
The management of GI-AI in children is challenging and many areas of uncertainty remain. Improving the knowledge on long-term GC effects on HPA in children, the management of steroid discontinuation and emergency dosing may help preventing GI-AI symptoms and acute hospital admission for AC.
糖皮质激素(GCs)常用于多种儿童急慢性疾病。然而,长期治疗可能导致下丘脑 - 垂体 - 肾上腺轴(HPA)功能障碍。糖皮质激素诱导的肾上腺皮质功能不全(GI - AI)确实是儿童肾上腺皮质功能不全(AI)最常见的原因,可能导致诸如肾上腺危象(AC)等危及生命的事件。它通常被低估,尤其是在使用非全身性糖皮质激素制剂时。本综述旨在总结关于长期GC治疗对HPA轴的影响、GC减量管理及HPA恢复评估的现有证据。
我们对聚焦于GI - AI的发病机制、预测因素、诊断和治疗的相关文献进行了叙述性综述。
所有类型的GCs,无论给药途径如何,都可能对HPA轴有抑制作用,尤其是使用高效能和长半衰期的化合物时。此外,长期GC给药是儿童库欣综合征最常见的原因。为了克服GI - AI的风险,缓慢停用GCs是必要的。当接近替代剂量时,建议改用半衰期较短的制剂,如氢化可的松。通过基础和刺激后的皮质醇水平评估HPA轴恢复情况,可能有助于检测有AC风险且可能需要补充氢化可的松的儿童。
儿童GI - AI的管理具有挑战性,仍存在许多不确定领域。提高对长期GC对儿童HPA影响的认识、类固醇停药管理和紧急给药,可能有助于预防GI - AI症状和因AC导致的急性住院。